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Abstract
Background: Glatiramer acetate (GA) and interferon-beta (INFb) are first-line disease modifying drugs for relapsing
remitting multiple sclerosis (RRMS). Treatment with INFb is associated with a significant increase in health-related
quality of life (HR-QoL) in the first 12 months. It is not known whether HR-QoL increases during treatment with GA.
Methods: 197 RRMS patients, 106 without and 91 with prior immunomodulation/immunosuppression, were
studied for HR-QoL (Leeds Multiple Sclerosis-QoL [LMS-QoL] scale, score range 0 - 32), fatigue (Fatigue Impact Scale
[FIS]) and depressed mood (Beck Depression Inventory-Short Form [BDI-SF]) at baseline and 6 and 12 months after
start of GA treatment.
Results: At 6 and 12 months mean LMS-QoL scores were significantly increased in the treatment-naive patient
group (p < 0.001), not in the pre-treated group. At month 12 43% of treatment-naïve patients had improved HR-
QoL (increase LMS-QoL score 3 or more points) (p < 0.001). Likewise, mean FIS scores were decreased at months 6
and 12 in the treatment-naïve group (p < 0.01), not in the pre-treated group. In both groups mean BDI-SF scores
did not change. No demographic or clinical baseline factor was predictive of HR-QoL increase. HR-QoL changes
were zero to negative for patients who had discontinued GA before month 12 (28.4% of patients).
Conclusions: In RRMS patients without prior immunomodulation/immunosuppression treatment with GA was
associated with an increase in HR-QoL in the first 6 months, that was sustained at 12 months. In 4 out of 10
patients HR-QoL improved. Increase in HR-QoL was associated with decrease in fatigue.
Introduction
T h ee f f i c a c yo ft h ed i s e a s em o d i f y i n gd r u g( D M D )g l a -
tiramer acetate (GA) in reducing relapses in relapsing
remitting multiple sclerosis (RRMS) has been demon-
strated in randomized placebo-controlled trials [1,2].
Studies on the effectiveness of GA treatment in daily
neurological practice have concentrated on relapses, dis-
ability, fatigue [3-5], work absenteeism [4] and cost-
effectiveness [6,7].
Health-related quality of life (HR-QoL) is an overall
measure of effectiveness from a patient’s perspective and
is becoming increasingly important in the assessment of
therapies in chronic disorders. It has been demonstrated
that in MS patients treatment with the DMD interferon-
beta (INFb) is associated with an increase in HR-QoL
[8,9]. Data on HR-QoL during GA treatment are scarce
and not informative [8,10].
Fatigue and depression are primary determinants of
impaired HR-QoL in MS [11]. Fatigue is reported by
over 80% of patients [12] and often interferes with social
or occupational activities [13]. It has been suggested that
GA may improve MS-related fatigue [3,4]. Depressive
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lence of major depressive disorders being 22% [14].
To investigate the overall benefit RRMS patients per-
ceive from GA treatment we performed a prospective,
observational, international, multi-centre study in
patients treated with GA in daily practice, focusing on
HR-QoL, fatigue, and depression (FOCUS study). Two
groups were studied, patients with prior immunomodu-
lation/immunosuppression (pre-treated group) and
patients without such treatment (treatment-naïve group)
[15]. Here we report the results.
Methods
Study and study populations
Investigator-initiated, prospective, observational, interna-
tional, multi-centre study. Patients were recruited in
out-patient departments from general hospitals, aca-
demic hospitals and MS centers in the Netherlands,
Sweden and Belgium. The protocol was submitted to
the Independent Review Board (IRB), an approved ethi-
cal committee residing in Amsterdam, the Netherlands.
The IRB concluded that, because of the observational
design of the study, a review by an ethical committee
was not required. The study did not qualify for being
tested according to the Dutch Medical Research Invol-
ving Human Subjects Act of 1999 [16]. Patients signed
an informed consent form before any study related pro-
cedure was performed. The study was carried out in
compliance with the Helsinki Declaration. The study
w a sf u n d e db yu n r e s t r i c t e dg r a n t sf r o mT E V AP h a r m a
Netherlands, Sweden and Belgium.
Inclusion criteria: 1) 18 years or older, 2) Expanded
Disability Status Scale (EDSS) score less than 5.5, and 3)
relapse- and steroid-free for at least 30 days. Exclusion
criteria: 1) hypersensitivity to GA or mannitol, 2) pre-
vious treatment with GA, and 3) pregnancy or lactation.
HR-QoL, fatigue, depression, disability and relapses
were assessed at baseline and at 6 and 12 months. In
case of a relapse a scheduled study visit was postponed
until at least 30 days after recovery.
In 29 centers 42 investigators, members of the FOCUS
study group, enrolled 106 treatment-naïve and 91 pre-
treated patients (Table 1). One-hundred-thirty-five
patients were included in the Netherlands, 42 in Sweden
and 20 in Belgium.
Outcome measures and assessments
HR-QoL was assessed by the Leeds Multiple Sclerosis
Quality of Life (LMS-QoL) scale. In 2000 the LMS-QoL
scale was developed in a community-based population
of people with MS [17]. The scale has been subjected to
standard psychometric testing of validity and reliability
and to Rasch analysis. It was found to fit the Rasch
model and had a close association to well being, with
good internal consistency and test-retest reliability. It is
a self-assessment scale that consists of eight questions,
examining MS-related aspects of QoL over the past
month. The LMS-QoL is easy to use and practical to
administer in a clinic setting or as postal questionnaire
[17]. Answers are rated on a 5-point scale from 0 to 4.
The resulting score ranges from 8 to 32, with higher
scores reflecting higher levels of well being. It returned
normally distributed scores when tested in a population
of MS patients [18], without significant floor or ceiling
effects. In a study of MS patients with acute relapses, it
was found to be responsive to change with higher effect
sizes than the Euro-Qol instrument and all of the sub-
scales of the MSQoL-54 [19], except measuring social
function [20]. In a separate study it showed significant
correlation with a detailed impact diary [21].
Fatigue was assessed by the Fatigue Impact Scale (FIS)
[22]. The FIS is a validated questionnaire examining
perception of fatigue over the past month and consists
of a total of 40 questions in 3 domains: cognitive, physi-
cal and social. Answers are rated on a 5-point scale (0
to 4). Total FIS score ranges from 0 to 160 and higher
total score indicates more experienced fatigue. The FIS
is widely accepted for assessment of fatigue in patients
with MS [3,23].
Depression was assessed by the Beck Depression
Inventory-Short Form (BDI-SF). The BDI-SF is a short
validated questionnaire of 13 questions [24,25]. Answers
are rated on a 4-point scale (0 to 3). Total score ranges
from 0 to 39 and higher scores indicate more depressed
mood.
Disability was assessed by the Guy’s Neurological Dis-
ability Scale (GNDS), a validated questionnaire
Table 1 Demographic and neurological characteristics of
patient groups
Total
group
Treatment-
naive
group
Pre-
treated
group
N = 197 N = 106 N = 91
Gender Female
(%)
151 (76.6) 81 (76.4) 70 (76.9)
Male (%) 46 (23.4) 25 (23.6) 21 (23.1)
Age (years) Mean
(SD)
38.6 (9.6) 38.5 (9.9) 38.8 (9.2)
Disease duration
(years)*
Mean
(SD)
4.3 (4.7) 2.7 (4.0) 6.3 (4.8)
GNDS score* Mean
(SD)
10.34
(5.56)
8.75 (4.60) 12.19
(6.01)
EDSS score Mean
(SD)
2.5 (1.42) 2.2 (1.14) 2.9 (1.65)
ARR Mean
(SD)
1.15 (0.62) 1.13 (0.50) 1.18 (0.73)
SD, standard deviation; GNDS, Guy’s Neurological Disability Scale; EDSS,
Expanded Disability Status Scale; ARR, annualized relapse rate. *, P < 0.05 for
differences between treatment-naïve and pre-treated groups.
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ranges from 0 to 60, where higher scores indicate
increased disability. The GNDS has a good correlation
to EDSS [27]. EDSS was assessed at baseline.
LMS-QoL, FIS and BDI-SF were completed by
patients at home within 7 days before study visit or at
the clinic just prior to the visit. Investigators completed
the GNDS by interview during visits.
Statistical analyses
Changes from baseline were calculated for the total
group, treatment-naïve group, and pre-treated group.
Given the statistically significant differences in baseline
characteristics for pre-treated and treatment-naïve
patient groups, differences during treatment were not
statistically tested.
Changes are given as mean value ± standard deviation
(SD) with 95% confidence interval (CI) for the mean
change. If a 95% CI for the mean change does not
include zero the change may be considered significant
in an exploratory manner since no adjustments for mul-
tiple testing were applied. When a patient terminated
GA treatment before month 12 a final assessment
occurred as for the next visit (month 6 or 12) and Last
Observation Carried Forward was applied. In a post-hoc
analysis demographics and LMS-QoL scores were inves-
tigated separately for patients who continued vs. patients
who discontinued GA.
In individual patients an increase in LMS-QoL score of
3 or more points was classified as improvement, decrease
of 3 or more points as worsening. Within each group a
Wilcoxon signed-rank test was performed to assess
whether there was a tendency different from ‘no change’.
Logistic regression analysis was applied to determine
whether predefined factors - age, gender, disease dura-
tion, prior treatment and baseline scores for FIS, BDI-
SF, GNDS and EDSS - were predictive of LMS-QoL
change.
Results
Baseline and discontinuation data
Most pre-treated patients (94.5%) had received immuno-
modulation, mainly IFNb. Five patients (5.5%) had
received mitoxantrone or methotrexate. The pre-treated
group had higher mean values for disease duration and
disability than the treatment-naïve group (Table 1).
One-hundred-forty-one patients (71.6%) completed 12
months treatment: 83 treatment-naïve (78.3%) and 58
pre-treated (63.7%). Reasons for discontinuation of GA
treatment were side effects (n = 41), lack of effectiveness
(n = 5), wish for pregnancy (n = 2), withdrawal of con-
s e n t( n=1 ) ,d e a t h( n=1 )o ru n k n o w n( n=6 ) .A l l
patients who completed 12 months GA treatment also
completed study participation.
HR-QoL
Values for LMS-QoL at baseline, month 6 and month
12 and changes from baseline are given in table 2.
Both at 6 and 12 months mean LMS-QoL scores were
significantly increased in the treatment-naive and the
total group, not in the pre-treated group (Table 2).
At month 6 41 patients (44.1%) in the treatment-naïve
group had improved HR-QoL, whereas HR-QoL was
unchanged in 43 (44.2%) and had worsened in 9 (9.7%)
(p < 0.001). For pre-treated patients there was no cen-
tral tendency different from ‘no change’ (p = 0.23). In
the total group 61 patients (35.5%) had improved, 89
( 5 1 . 7 % )w e r eu n c h a n g e da n d2 2( 1 2 . 8 % )h a dw o r s e n e d
(p < 0.001).
At 12 months results were similar. In the treatment-
naïve group 42 patients (42.9%) had improved HR-QoL,
while 44 (44.9%) had unchanged and 12 (12.2%) wor-
sened HR-QoL (p < 0.001). No such tendency was seen
in pre-treated patients (p = 0.13). In the total group 64
patients (35.8%) had improved, 90 (50.3%) were
unchanged, and 25 (14.0%) had worsened (p < 0.001).
A post hoc analysis was performed comparing patients
who had completed 12 months treatment (71.6%) to
those who had discontinued treatment (28.4%). Non-
completion was more frequent in pre-treated (36.3%)
than in treatment-naïve patients (22.0%). In both groups
LMS-QoL changes were about 2 points more advanta-
geous for completers than for non-completers. Mean
changes were close to zero or slightly negative for non-
completers, while results for completers were even
slightly better than unstratified values (Table 3).
Multiple regression models not including baseline HR-
QoL as additional factor explained less than 15% of
variability of HR-QoL changes. The improved perfor-
mance of models including baseline HR-QoL - still not
explaining more than 40% of variability - relates to the
fact that patients with low baseline HR-QoL have a bet-
ter chance for improvement.
Fatigue and depression
Table 4 shows FIS values in treatment-naïve, pre-treated
and total patient groups at baseline, month 6 and
month 12, and changes from baseline.
At month 6 mean total FIS score had decreased in the
treatment-naïve, pre-treated, and total groups. At month
12, compared to baseline, mean total FIS score had
decreased in the treatment-naïve group and the total
group, not in the pre-treated group.
At baseline mean BDI-SF score in the treatment-naive
group was 5.81 (SD 4.03), in the pre-treated group 7.47
(SD 5.29), and in the total group 6.58 (SD 4.72). There
were no statistically significant changes at month 6 or
12 in any group.
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At 6 months mean GNDS score in the treatment-naïve
group (7.40; SD 4.80) and in the total group (9.57, SD
6.00) were lower than at baseline (p = 0.001 and p =
0.01, resp.). Other changes were not statistically
significant.
Annualized relapse rate (ARR) over the study period
was 0.69 (SD 0.96) in the treatment-naïve group, 1.03
(SD 1.22) in the pre-treated group, and 0.84 (SD 1.09)
in the total group.
Discussion
We observed a mean increase in HR-QoL in treatment-
naïve RRMS patients 6 months after start of GA treat-
ment, that was sustained at 12 months. Both mean and
median HR-QoL values were higher than at baseline,
suggesting that the increase was a group phenomenon,
rather than caused by individual outliers. HR-QoL
increase was paralleled by a decrease in experienced fati-
gue, whereas levels of depressed mood remained
unchanged.
In a single-centre study Lily et al. assessed HR-Qol in
210 RRMS patients before and during treatment with
disease modifying drugs (DMD) - intramuscular (IM)
INFb-1a, subcutaneous INFb-1a, subcutaneous INFb-1b,
GA - and found that DMD treatment was associated
with an increase in HR-QoL [8]: Mean HR-QoL score
increased significantly at one month, further increasing
to a peak at nine months, and remaining significantly
elevated at three years. The small number - eight - of
GA-treated patients in their study did not allow for con-
clusions with respect to GA. Our data show that
Table 2 LMS-QoL values and changes from baseline
Time points and periods Parameters Total group Treatment-naive
group
Pre-treated
group
Baseline (B) Mean (SD) 19.51 (4.19) 19.54 (4.26) 19.47 (4.12)
Median 19.00 20.00 19.00
95% CI (mean) 18.92; 20.10 18.72; 20.36 18.61; 20.33
Month 6 (M6) Mean (SD) 20.95 (4.63) 21.35 (4.63) 20.48 (4.61)
Median 21.00 22.00 21.00
95% CI (mean) 20.26; 21.65 20.40; 22.31 19.45; 21.51
Month 12 (M12) Mean (SD) 20.94 (4.69) 21.73 (4.76) 19.98 (4.43)
Median 21.00 21.50 20.00
95% CI (mean) 20.25; 21.63 20.78; 22.69 19.00; 20.96
Change B to M6 Mean (SD) 1.41 (3.97)* 1.90 (4.08)* 0.82 (3.77)
Median 1.00 1.00 1.00
95% CI (mean) 0.81; 2.00 1.06; 2.74 -0.02; 1.67
Change B to M12 Mean (SD) 1.33 (4.24)* 2.10 (4.56)* 0.40 (3.64)
Median 1.00 1.00 1.00
95% CI (mean) 0.70; 1.96 1.19; 3.02 -0.41; 1.20
SD, standard deviation; CI, confidence interval; *, p < 0.001. Differences between groups were not statistically tested.
Table 3 LMS-QoL values for completers vs. non-completers and percentages of patients with improved, unchanged
and worsened HR-QoL at month 12
LMS-QoL Parameters Total group
completers
Total group non-
completers
Treatment-naive
completers
Treatment-naive non-
completers
Baseline (B) Mean (SD) 19.84 (4.15) 18.66 (4.20) 19.59 (4.23) 19.35 (4.49)
Median 20.00 19.00 19.00 20.00
95% CI
(mean)
19.15; 20.54 17.54; 19.79 18.67; 20.51 17.41; 21.29
Change B to
M12
Mean (SD) 1.76 (4.25)* -0.21 (3.91) 2.52 (4.72)* -0.06 (2.91)
Median 1.00 0.00 2.00 0.00
95% CI
(mean)
1.05; 2.47 -1.47; 1.06 1.49; 3.56 -1.61; 1.49
Improved M12 n (%) 59 (42.1) 5 (12.8) 40 (48.8) 2 (12.5)
Unchanged n (%) 65 (46.4) 25 (64.1) 34 (41.5) 10 (62.5)
Worsened n (%) 16 (11.4) 9 (23.1) 8 (9.8) 4 (25.0)
*, p < 0.001.
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GA treatment. Moreover, our finding that HR-QoL was
i n c r e a s e da t6m o n t h sa n dr e m a i n e de l e v a t e da t1 2
months is in agreement with the pattern described by
Lily et al. [8].
It has been known that the relationship between dis-
ability and HR-QoL in MS is complex [28]. In treat-
ment-naive patients we observed an improvement of
mean disability score (GNDS) at 6 months, but not at
12 months. In their study Lily et al. found no significant
change in median disability (EDSS) throughout the three
year study period [8]. Likewise, we found that disability
remained unchanged in RRMS patients during two years
of treatment with IM INFb-1a, whereas mean physical
and mental HR-QoL scores (MS54-QoL) improved sig-
nificantly [9]. In fact, as prevention of disability progres-
sion is a primary goal of DMD treatment, staying
clinically stable is per se a beneficial phenomenon.
Patients may experience stability as a relative improve-
ment, that positively affects HR-QoL.
No baseline characteristic was predictive of HR-QoL
increase, except for low HR-QoL. In contrast, in a study
in IM INFb-1a-treated RRMS patients it was found that
increase in HR-QoL was associated with young age and
low baseline disability [9]. Lily et al. performed multiple
regression analysis of baseline characteristics against
change in HR-QoL score over the first two years of
treatment with DMD [8]. There was no relationship
with age, disease duration, disability or number of
relapses, and - similar to out finding - the only signifi-
cant variable predicting a good QoL response was low
QoL [8]. In all, age, disease duration, disability, fatigue
or depressed mood are characteristics that are not
helpful in selecting patients for GA treatment in terms
of QoL improvement.
After 12 months treatment-naive patients showed a
mean increase in LMS-QoL score of about 11%. It is
not known what change in HR-QoL is relevant for indi-
vidual MS patients. In general, changes of 10% to 15%
in clinical outcomes may be considered meaningful. We
choose a minimum of 15% of the mean baseline LMS-
QoL score in the total population (19.51), being 3
points, for an individual change to be qualified as
improvement or worsening. Thus, after one year 4 out
of 10 treatment-naive patients had an improved HR-
QoL and only 1 out of 10 a worsened HR-QoL. In
patients who had completed 12 months treatment
changes were even more advantageous, whereas for
non-completers mean changes were close to zero or
even negative. As most patients who discontinued GA
did so because of side effects (73%), in non-completers
the negative impact of side effects on HR-QoL may
have outweighed GA’s positive effect [29]. Moreover,
treatment discontinuation could have prevented the full
development of GA’s beneficial effect, as it is known
that relapse reduction occurs not sooner than after 6
months.
Interestingly, in patients with prior immunomodula-
tion/immunosuppression mean HR-QoL did not change
significantly. This could be explained by several factors.
First, overrepresentation in this group of patients with
more active inflammation, as it is likely that a substan-
tial number of patients had stopped previous treatment
for reason of incomplete response. In spite of prior
treatment, pre-study relapse rate in this group was simi-
lar to that in naive patients and on-study relapse rate
Table 4 FIS values and differences from baseline
Time points and periods Parameters Total Group Treatment-naive group Pre-treated group
Baseline (B) Mean (SD) 60.53 (34.24) 56.25 (32.65) 65.51 (35.54)
Median 59.00 55.00 70.00
95% CI (mean) 55.72; 65.34 49.97; 62.54 58.10; 72.91
Month 6 (M6) Mean (SD) 51.15 (35.35) 45.68 (33.33) 57.79 (36.76)
Median 44.50 40.00 50.00
95% CI (mean) 45.83; 56.47 38.81; 52.54 49.36; 65.83
Month 12 (M12) Mean (SD) 54.07 (35.18) 47.97 (33.78) 61.46 (35.62)
Median 49.00 43.50 63.00
95% CI (mean) 48.88; 59.26 41.20; 54.74 53.58; 69.33
Change B to M6 Mean (SD) -9.17 (27.08)*** -11.33 (27.67)*** -6.62 (26.32)*
Median -6.00 -7.00 -3.00
95% CI (mean) -13.24; -5.09 -17.03; -5.64 -12.51; -0.73
Change B to M12 Mean (SD) -6.04 (29.04)** -8.50 (29.35)** -3.06 (28.57)
Median -5.00 -8.00 -3.00
95% CI (mean) -10.32; -1.76 -14.38; -2.62 -9.38; 3.25
SD, standard deviation; CI, confidence interval; ***, p < 0.001; **, p < 0.01; *, p < 0.05. Differences between groups were not statistically tested.
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haps more modest in this group, as patients had had the
disappointing experience of treatment failure, although
w et h i n ki tu n l i k e l yt h a ta t1 2m o n t h sas i g n i f i c a n tp l a -
cebo effect was still at work in either group. Third,
unchanged HR-QoL may relate to the higher rate of
non-completers in this group (36%).
At 12 months treatment-naive patients showed a sig-
nificant decrease in fatigue. Decreased fatigue in MS
patients during the first year of GA treatment has been
reported by others [3,4]. Our observation that a decrease
in fatigue was associated with an increase in HR-QoL
suggests that a decline in experienced fatigue contri-
butes to HR-QoL improvement.
Our study does not inform on HR-QoL beyond the
first year of GA treatment. Comparison with the report
by Lily et al. shows a similar pattern of early increase in
the first 6 months, that is sustained at 12 months, which
suggests that this early gain in HR-QoL may be sus-
tained further [8]. Yet, future studies are needed to
establish the long-term change in HR-QoL during GA
treatment.
In order to weigh expected benefits against risks
patients need quantified inf o r m a t i o no ne f f e c t i v e n e s s
before deciding to start DMD treatment. Randomized
controlled trials (RCTs) investigate efficacy and mostly
do not include overall or patient-centred measures.
Moreover, RCT data are obtained in settings not repre-
sentative of daily practice and thus difficult to general-
ize. Observational data obtained in ‘real-life’ are more
informative on a patient’s chance to reach a pre-defined
therapeutic goal. As our patients were treated in daily
care settings, this study’s results may be considered
representative of GA treatment in real life.
Conclusion
In treatment-naïve RRMS patients treatment with GA
was associated with an increase in HR-QoL in the first 6
months, that was sustained at 12 months. Moreover,
increase in HR-QoL was associated with decrease in
fatigue. Our finding in this group that 4 out of 10
patients had improved HR-QoL 12 months after start of
GA treatment suggests that clinically active RRMS
patients without prior immunomodulation/immunosup-
pression have approximately 40% chance of improved
HR-QoL one year after start of GA treatment. This
information may be helpful to neurologists and patients
when considering immunomodulating treatment.
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